JP6534660B2 - 拘束場を生成するシステムおよびそれを実装する医療装置 - Google Patents
拘束場を生成するシステムおよびそれを実装する医療装置 Download PDFInfo
- Publication number
- JP6534660B2 JP6534660B2 JP2016524845A JP2016524845A JP6534660B2 JP 6534660 B2 JP6534660 B2 JP 6534660B2 JP 2016524845 A JP2016524845 A JP 2016524845A JP 2016524845 A JP2016524845 A JP 2016524845A JP 6534660 B2 JP6534660 B2 JP 6534660B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- nanoparticles
- magnetic field
- composition
- medical system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 178
- 239000002105 nanoparticle Substances 0.000 claims description 112
- 210000004881 tumor cell Anatomy 0.000 claims description 32
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 230000000717 retained effect Effects 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 229910052742 iron Inorganic materials 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010020843 Hyperthermia Diseases 0.000 claims description 4
- 230000036031 hyperthermia Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000002872 contrast media Substances 0.000 claims description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 description 63
- 241000699670 Mus sp. Species 0.000 description 22
- 201000011510 cancer Diseases 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011729 BALB/c nude mouse Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 241000321096 Adenoides Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- -1 arginyl glycyl aspartate Chemical compound 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011806 swiss nude mouse Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Treatment Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176364.1A EP2823858A1 (en) | 2013-07-12 | 2013-07-12 | System generating a constraint field, and medical device implementing the same |
| EP13176364.1 | 2013-07-12 | ||
| PCT/EP2014/064995 WO2015004285A1 (en) | 2013-07-12 | 2014-07-11 | System generating a constraint field, and medical device implementing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532674A JP2016532674A (ja) | 2016-10-20 |
| JP2016532674A5 JP2016532674A5 (enExample) | 2017-07-20 |
| JP6534660B2 true JP6534660B2 (ja) | 2019-06-26 |
Family
ID=48793929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524845A Expired - Fee Related JP6534660B2 (ja) | 2013-07-12 | 2014-07-11 | 拘束場を生成するシステムおよびそれを実装する医療装置 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10449160B2 (enExample) |
| EP (2) | EP2823858A1 (enExample) |
| JP (1) | JP6534660B2 (enExample) |
| WO (1) | WO2015004285A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10660975B2 (en) | 2016-10-21 | 2020-05-26 | Nanobacterie | Magnetic nanoparticles for destroying pathological cells in an individual |
| EP4302820A3 (en) * | 2016-11-24 | 2024-03-06 | Public University Corporation Yokohama City University | Cancer treatment apparatus |
| WO2019104579A1 (en) * | 2017-11-30 | 2019-06-06 | SHIEH, Darbin | Method for predicting and modulating susceptibility of cancer cell to programmed cell death |
| EP4292660A1 (de) | 2022-06-13 | 2023-12-20 | Fortis GmbH | System zur verabreichung eines wirkstoffs |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
| AU4305101A (en) * | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
| AU2003900335A0 (en) * | 2003-01-22 | 2003-02-13 | Sirtex Medical Limited | Microparticles for selectively targeted hyperthermia |
| JP2009114066A (ja) * | 2006-02-24 | 2009-05-28 | International Medical Center Of Japan | 機能性分子が導入された有機磁性ナノ複合体 |
| FR2897931B1 (fr) * | 2006-02-24 | 2008-05-09 | Technologie Alpine De Securite | Dispositif de declenchement d'avalanche |
| EP1852107A1 (en) | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| EP1988156A1 (en) * | 2007-04-30 | 2008-11-05 | Brossel, Rémy | Cell construct, its process of manufacture, as well as a device, implant and processes for the mechanical stimulation of cells in vitro and in vivo |
| WO2009076465A1 (en) * | 2007-12-11 | 2009-06-18 | University Of Maryland, College Park | Methods and systems for magnetic focusing of therapeutic, diagnostic or prophylactic agents to deep targets |
| DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
| EP2508171B1 (en) | 2011-03-25 | 2014-05-07 | Universitätsklinikum Erlangen | Pharmaceutical magnetic nano-particle composition |
-
2013
- 2013-07-12 EP EP13176364.1A patent/EP2823858A1/en not_active Withdrawn
-
2014
- 2014-07-11 EP EP14738529.8A patent/EP3019236A1/en active Pending
- 2014-07-11 US US14/904,580 patent/US10449160B2/en not_active Expired - Fee Related
- 2014-07-11 JP JP2016524845A patent/JP6534660B2/ja not_active Expired - Fee Related
- 2014-07-11 WO PCT/EP2014/064995 patent/WO2015004285A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20160143859A1 (en) | 2016-05-26 |
| US10449160B2 (en) | 2019-10-22 |
| WO2015004285A1 (en) | 2015-01-15 |
| EP2823858A1 (en) | 2015-01-14 |
| JP2016532674A (ja) | 2016-10-20 |
| EP3019236A1 (en) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gavilán et al. | Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer | |
| Cheng et al. | Advances in magnetic nanoparticle‐mediated cancer immune‐theranostics | |
| Farzanegan et al. | Evaluating the applications and effectiveness of magnetic nanoparticle-based hyperthermia for cancer treatment: A systematic review | |
| Alexiou et al. | Cancer therapy with drug loaded magnetic nanoparticles—magnetic drug targeting | |
| Jordan et al. | The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma | |
| Sohail et al. | A review on hyperthermia via nanoparticle-mediated therapy | |
| Datta et al. | Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich’s “magic (nano) bullet” for cancer theranostics? | |
| Liu et al. | Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain | |
| Subramani et al. | Targeting nanoparticles as drug delivery systems for cancer treatment | |
| Alshareeda et al. | Nanotechnology: A revolutionary approach to prevent breast cancer recurrence | |
| Elsherbini et al. | Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging | |
| JP2010516705A (ja) | 温熱療法におけるサセプタとその使用法 | |
| Shirangi et al. | Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer | |
| Zhao et al. | Multifunctional magnetic nanoparticles for simultaneous cancer near-infrared imaging and targeting photodynamic therapy | |
| JP6534660B2 (ja) | 拘束場を生成するシステムおよびそれを実装する医療装置 | |
| Rivera et al. | Neurosurgical applications of magnetic hyperthermia therapy | |
| WO2013170379A1 (en) | Drug delivery across the blood-brain barrier using magnetically heatable entities | |
| Sawant et al. | Cancer research and therapy: Where are we today | |
| Thirumurugan et al. | Angiopep-2-decorated titanium–alloy core–shell magnetic nanoparticles for nanotheranostics and medical imaging | |
| Yang et al. | Advances in magnetic nanoparticles for molecular medicine | |
| Jordan et al. | Magnetic fluid hyperthermia (MFH) | |
| Carofiglio et al. | Targeted lipid-coated ZnO nanoparticles coupled with ultrasound: a sonodynamic approach for the treatment of osteosarcoma as 3D spheroid models | |
| Etli Omur et al. | Magnetic nanoparticles for diagnosis and treatment | |
| Estelrich et al. | Magnetic nanoparticles as delivery systems to penetrate the blood-brain barrier | |
| Zhao et al. | Thermochemotherapy mediated by novel solar-planet structured magnetic nanocomposites for glioma treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170608 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190408 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190521 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190529 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6534660 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |